PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Files An 8-K Entry into a Material Definitive Agreement

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item 1.01 Entry into a Material Definitive Agreement.

On May 22, 2017, PetLife Pharmaceuticals, Inc. (PetLife) and Dr.
Ralph T. Salvagno, Dr. Vivekananda Ramana, and Dr. Baidvanath
Mishra (collectively, Drs. Salvagno, Ramana and Mishra), entered
into an Assignment Agreement in regards to the following:

On March 31, 2017, a patent was filed for the treatment of
cancer in pets, combining chlorotoxin and plant-based
therapeutics. The patent was filed in India titled A
Composition for Targeting Cancer in Canines and Humans
The patent protection is for both process and composition
thus protecting not only the physical elements of the
formulation but also the process by which they are combined.
This new patent pending advanced formulation will be the
basis for PetLifes product, Vitalzul, for the proposed
treatment of certain cancers in dogs and cats. The human
application will be addressed by management at a later date.
On May 9, 2017, the identical patent as filed in India, was
filed with the United States Patent and Trademark Office.

The Assignment Agreement between PetLife and Drs. Salvagno,
Ramana and Mishra provided an irrevocable assignment of all
rights of the patent, which will be effected simultaneous with
the issuance of each patent. Drs. Salvagno, Ramana and Mishra, in
conjunction with the assignment, will be reimbursed for all
expenses related to developing the intellectual property used as
a basis for the patent, as well as other applicable expenses
related to the patent.

Dr. Ralph Salvagno is the Chief Executive Officer and a Director
of PetLife. Dr. Ramana is the Chief Medical Officer of PetLife.

Item 9.01 Financial Statements and Exhibits.

The exhibits listed in the following Exhibit Index are filed as
part of this report:

Exhibit No. Description
10.6 Assignment Agreement between PetLife Pharmaceuticals, Inc.
and Dr. Ralph T. Salvagno dated May 22, 2017
10.7 Assignment Agreement between PetLife Pharmaceuticals, Inc.
and Dr. Vivekananda Ramana dated May 22, 2017
10.8 Assignment Agreement between PetLife Pharmaceuticals, Inc.
and Dr. Baidvanath Mishra dated May 22, 2017
99.1 Press Release titled PetLife Files for Patent for the
Treatment of Cancer for Pets as released on May 30, 2017

About PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF)

PetLife Pharmaceuticals, Inc., formerly Clear TV Ventures, Inc., is engaged in the development and launching of a high potency (HP) veterinary cancer medications and nutraceuticals, based on the formula Escozine. The Company’s formula, Escozine (for humans) is sold as either a nutraceutical or prescription drug in approximately 40 countries, including the United States. It has rights to formulate, package and market a product line, Escozine for Pets, for livestock suffering from cancer. Escozine for Pets is a natural product containing serum derived from the Caribbean Blue Scorpion and polarized using the Company’s polarization technology. It intends to target various veterinary cancers, including Lymphoma, Osteosarcoma, Mast Cell Tumor, Melanoma, Squamous Cell Carcinoma, Mammary Carcinoma, Transitional Cell Carcinoma and Soft Tissue Sarcoma. It has designed three products for differentiated intake protocols for home and veterinary usage: Oral/Rectal, Patch and Injectable.

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Recent Trading Information

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) closed its last trading session 00.000 at 0.360 with 187,378 shares trading hands.

An ad to help with our costs